Home
Help
Search
Login
Register
Unanswered Topics11
News:
New Search Options: ISE (posts), +pdf, +misc (text), +mega (all 3), +media (audio & visual) non-Default dropdown options (enter '/help' within ISE)
🧾✨ Link to our Forum Charter: Read, Respect, Reflect
Solicitation and Dealing of Drugs is Strictly Prohibited !
Please email smfadmin if you wish to advertise here
Non drug topics are also very welcome !
All Terms and Conditions are at the Bottom of the Page
dopetalk does not endorse any advertised product nor does it accept any liability for it's use or misuse
Our Discord Notification Server invitation link is https://discord.gg/jB2qmRrxyD
|
| # | File | Size | Downloads | Info | DL |
|---|---|---|---|---|---|
| 00 | instagram-1793840902339.jpg | 200.8 KB | 1 | ℹ️ | ⬇️ |
| 01 | instagram-1793840902439.jpg | 172.4 KB | 1 | ℹ️ | ⬇️ |
| 02 | instagram-1793840902539.jpg | 155.6 KB | 1 | ℹ️ | ⬇️ |
| 03 | instagram-1793840902640.jpg | 170.2 KB | 1 | ℹ️ | ⬇️ |
| 04 | instagram-1793840902740.jpg | 129.2 KB | 1 | ℹ️ | ⬇️ |
| 05 | instagram-1793840902840.jpg | 154.6 KB | 1 | ℹ️ | ⬇️ |
| 06 | instagram-1793840902940.jpg | 169.4 KB | 1 | ℹ️ | ⬇️ |
| 07 | instagram-1793840903040.jpg | 171.4 KB | 1 | ℹ️ | ⬇️ |
| 08 | instagram-1793840903140.jpg | 210.7 KB | 1 | ℹ️ | ⬇️ |
| 09 | instagram-1793840903240.jpg | 195 KB | 1 | ℹ️ | ⬇️ |
instagram-1793840902339.jpg (200.78 kB . 1254x1254 - viewed 2 times) instagram-1793840902439.jpg (172.4 kB . 1254x1254 - viewed 2 times) instagram-1793840902539.jpg (155.58 kB . 1254x1254 - viewed 2 times) instagram-1793840902740.jpg (129.22 kB . 1254x1254 - viewed 2 times) instagram-1793840902840.jpg (154.59 kB . 1254x1254 - viewed 2 times) instagram-1793840902940.jpg (169.41 kB . 1254x1254 - viewed 2 times) instagram-1793840903040.jpg (171.4 kB . 1254x1254 - viewed 2 times) instagram-1793840903140.jpg (210.69 kB . 1254x1254 - viewed 2 times) instagram-1793840903240.jpg (194.95 kB . 1254x1254 - viewed 2 times)15
Code Maintenance and Development / Who Downloaded Attachment
« Last post by smfadmin on Today at 12:54:51 AM »https://custom.simplemachines.org/index.php?mod=4146
Who Downloaded Attachment v1.1.18 Hooks only
This modification adds ability to show who downloaded attachment.
Compatible With 2.0.14, 2.0.15, 2.0.19, 2.1.7
Latest version v1.1.18
Shows members who downloaded an attachment: name, time and IP address.
Compatibility
SMF 2.0.19+ (PHP 5.4+)
SMF 2.1.x (PHP 7.1+)
After installation
Enable View attachment download list (show_download_list) for the required member groups.
Settings:
Cache lifetime for the list (default: 60 seconds).
Maximum age of records (0 = all).
Maximum number of rows (default: 1000).
Show IP addresses to administrators only.
Guest downloads are not logged. The history begins accumulating after installation.
Who Downloaded Attachment v1.1.18 Hooks only
This modification adds ability to show who downloaded attachment.
Compatible With 2.0.14, 2.0.15, 2.0.19, 2.1.7
Latest version v1.1.18
Shows members who downloaded an attachment: name, time and IP address.
Compatibility
SMF 2.0.19+ (PHP 5.4+)
SMF 2.1.x (PHP 7.1+)
After installation
Enable View attachment download list (show_download_list) for the required member groups.
Settings:
Cache lifetime for the list (default: 60 seconds).
Maximum age of records (0 = all).
Maximum number of rows (default: 1000).
Show IP addresses to administrators only.
Guest downloads are not logged. The history begins accumulating after installation.
16
Cannabis and Cannabinoids / Stoners vs Drinkers
« Last post by smfadmin on Yesterday at 11:07:32 PM »The two do not vibe with eachother
17
Pharmacology and Neurobiology / Brain Network Localization of Anhedonia
« Last post by smfadmin on Yesterday at 10:38:06 PM »📎 Click on me to view all my attachments
ListAttBBC | v7.3.0 | 2026-10-26 | Andrew.human & Claude.ai | live 13:33:48
| # | File | Size | Downloads | Info | DL |
|---|---|---|---|---|---|
| 00 | Ahnedonia.jpg | 371.1 KB | 1 | ℹ️ | ⬇️ |
| 01 | Brain network localization of anhedonia.pdf [native] [pdf in chunks] | 2.5 MB | 3 | ℹ️ | ⬇️ |
Spoiler: show
18
Artificial Intelligence / Deep Learning / LLMs Can Natively Read & Write Neural Network Weights !
« Last post by Chip on Yesterday at 09:49:42 PM »No Typical Training Needed !
19
Alerts / Drug-Related Deaths Remain at an All-Time High in England and Wales
« Last post by Chip on Yesterday at 09:40:26 PM »NB: Understand Cocaine's cardiotoxicity, speed is the safer (and much cheaper) alternative !
20
Suicide and Ideation / Could Ketamine+Buprenorphine Shift the Suicidal Outpatient Chrisis Paradigm ?
« Last post by Chip on Yesterday at 04:56:20 PM »📎 Click on me to view all my attachments
ListAttBBC | v7.3.0 | 2026-10-26 | Andrew.human & Claude.ai | live 13:33:48
| # | File | Size | Downloads | Info | DL |
|---|---|---|---|---|---|
| 00 | bridging_the_gap_after_a_suicidal_crisis.md | 7.1 KB | 0 | ℹ️ | ⬇️ |
Bridging Suicidal Crisis to Outpatient Care: Could Ketamine Plus Buprenorphine Shift the Paradigm ?
Oct 19, 2026
Some excerpts: (see the entire article at the source link above):
Acute suicidal crisis is a common, high-stakes presentation in emergency departments (EDs) across the US, with few treatment options for rapid and durable relief of symptoms. Due to the inconsistent availability of mental health care across the country, EDs represent a common first touchpoint for patients in suicidal crisis.
Current standard of care for patients in suicidal crisis is limited to determining the need for inpatient versus outpatient care, with few therapeutic interventions initiated in the ED. Patients requiring psychiatric hospitalization often remain in the ED for prolonged boarding while awaiting placement. While ketamine is well established to reduce suicidal ideation in outpatients with major depression and suicidal ideation within hours, there remain significant questions to be answered before its use can be adopted in ED patients.
In a recent randomized controlled trial, adjunctive low-dose buprenorphine following a single ketamine infusion may prolong reductions in suicidal ideation for up to 1 month (Tucciarone et al, 2026).1 However, these findings remain preliminary and require replication before clinical implementation. Here, we review the emerging evidence on therapeutic strategies that may help bridge patients presenting to the ED in suicidal crisis to outpatient care, consider the potential implications for emergency medicine clinicians, and highlight key priorities for future clinical trials.
Burden of Acute Suicidal Crises in EDs
Suicidal ideation and acute suicidal crisis are increasingly common reasons for ED visits.2 Nearly 1.4 million ED visits each year involve suicidal ideation or attempt, and that number continues to rise. For many patients, the ED is the first point of contact with the mental health system, yet treatment options in the acute setting remain limited.
Patients deemed to be at high risk for suicide are often held in the ED until an inpatient psychiatric bed becomes available. ED boarding, defined as the time between the decision to admit and transfer from the ED because no inpatient bed is available, has become increasingly common, increases emotional distress, delays definitive psychiatric care, contributes to ED crowding, and is associated with longer hospital stays and medication errors.3–5
Importantly, not every patient presenting to the ED with suicidal ideation benefits from inpatient psychiatric hospitalization.4 Treatments for suicidal crisis in the ED, whether pharmacologic or behavioral, are not widely available. Many patients leave the ED with limited access to outpatient psychiatric care, particularly in rural and underserved communities.6 Without timely follow-up, patients remain vulnerable to recurrent suicidal crises and repeat ED visits.7 Improving continuity of care after suicidal crisis remains a national priority.8
Ketamine: A Familiar Drug That Could Provide Rapid but Transient Relief
Current evidence suggests that for patients with treatment resistant depression with or without suicidal crisis, ketamine infusion can produce a rapid, yet transient antisuicidal effect in the outpatient setting.9–11 Unlike conventional antidepressants, a single dose of IV ketamine can reduce suicidal ideation within hours, and its effects may persist for 1 to 4 weeks.
Several factors make ketamine a potential choice for management of suicidal crisis in patients, particularly within EDs.
First, ketamine has a rapid onset, and whether or not a patient will respond to treatment could be determined within the first hours of an ED encounter.
Second, ketamine is already widely available for procedural sedation, analgesia, and management of severe agitation in nearly every ED across the US and is a drug with which ED physicians are already comfortable.
Third, small clinical trials suggest ketamine can be administered safely to patients with suicidal ideation in the ED.9,12,13 Finally, beyond reducing suicidal ideation, ketamine rapidly improves several symptoms such as depression, hopelessness, pessimism, and irritability, which suggests that its clinical benefit may extend beyond a single symptom domain.14,15
There remain significant unanswered questions before ketamine use for this indication can be widely adopted by ED clinicians. While ketamine is a promising candidate for investigation in ED patients, further trials, including that by Maguire (NCT06085937), remain ongoing to determine whether its benefits in outpatients will translate to an ED population of suicidal adults. While pilot studies show evidence of feasibility, robust evidence of feasibility and efficacy in an ED population remains needed.12,13 In addition, these studies commonly exclude patients who are intoxicated, have a history of psychosis, or have experienced recent manic episodes, limiting generalizability of findings to these populations.
Should ongoing trials support the use of ketamine for this indication, there remain questions to be addressed before widespread adoption of its use could be expected. Identifying which ED patients may or may not benefit from a trial of ketamine remains a challenge. In addition, while a single dose of ketamine can reduce suicidal ideation for up to several weeks, the range of efficacy is days to weeks, and ongoing care would need to be reliably and rapidly initiated.9 Like many ED-based therapies, a single dose of ketamine in the ED could not be considered definitive care, though it could start a bridge to outpatient rather than pursuing inpatient treatment for selected patients. Developing a robust outpatient pathway for continued care in those who respond to an initial dose of ketamine remains necessary.
Could a Pharmacologic Add-On Extend the Antisuicidal Effect of Ketamine ?
While the exact mechanism of ketamine’s action on depression and suicidal ideation remains largely unknown, it has been postulated that in addition to N-methyl-D-aspartate (NMDA) antagonism, ketamine may modulate the mu-and kappa-opioid systems, suggesting a complex antidepressant mechanism that may be augmented by additional treatments that target the opioid system.16 The recent randomized controlled trial by Tucciarone et al1 provides preliminary proof-of-concept evidence that adjunctive low-dose buprenorphine may prolong ketamine’s antisuicidal effects. Adults with major depressive disorder and suicidal ideation received a single IV ketamine infusion and were then randomized to 4 weeks of low-dose sublingual buprenorphine or placebo. Ketamine produced the previously evidenced rapid reduction in suicidal ideation, with both groups demonstrating a 60% reduction in suicidal symptoms within 48 hours. Patients treated with buprenorphine maintained this reduction for at least 31 days compared to those in the placebo group, who showed relapsing suicidal symptoms starting at 10-day follow-up.
These findings provide preliminary evidence that low-dose oral buprenorphine may prolong ketamine’s antisuicidal effects and could provide a pharmacologic bridge while patients establish or otherwise engage with ongoing psychiatric care. These findings should be considered hypothesis-generating and require replication in larger, multicenter studies before incorporation into routine clinical practice. Of note, the above study specifically excluded patients with diagnoses of substance use disorder. In studies examining ED patients presenting for suicidal ideation, up to 42% have a concomitant diagnosis of opioid use disorder.17 In one 2015 study of ultralow-dose buprenorphine as adjunctive treatment for severely suicidal patients with or without opioid use disorder, those randomized to receive buprenorphine had a greater reduction in suicidal ideation compared to placebo at 2 and 4 weeks without increase in withdrawal symptoms, suggesting that perhaps those with substance use disorder may also benefit from buprenorphine as adjunct treatment, though these findings require replication.18 In addition, while major depression is common in those presenting for suicidal ideation to the ED, not all suicidal crises occur in the setting of ongoing major depression or bipolar depression. In order to translate the above findings to an ED pathway, further study would need to be undertaken to identify which ED patients could potentially see similar benefit from buprenorphine add-on therapy to ketamine.
Need help or a chat ?
If you need any help or a chat then IM/PM or email me, Chip
dopetalk does not endorse any advertised product nor does it accept any liability for it's use or misuse
TERMS AND CONDITIONS
In no event will d&u or any person involved in creating, producing, or distributing site information be liable for any direct, indirect, incidental, punitive, special or consequential damages arising out of the use of or inability to use d&u. You agree to indemnify and hold harmless d&u, its domain founders, sponsors, maintainers, server administrators, volunteers and contributors from and against all liability, claims, damages, costs and expenses, including legal fees, that arise directly or indirectly from the use of any part of the d&u site.
TO USE THIS WEBSITE YOU MUST AGREE TO THE TERMS AND CONDITIONS ABOVE
Founded December 2014